Zimmerman H J
Drugs. 1978 Jul;16(1):25-45. doi: 10.2165/00003495-197816010-00002.
The large number of chemical agents administered for therapeutic or diagnostic purposes can produce various types of hepatic injury by several mechanism. Acute injury may be cytotoxic, cholestatic or mixed. Cytotoxic injury may consist of necrosis or steatosis. Cholestatic injury may be cholangiolitic (hepatocanalicular) or bland (canalicular). Chronic hepatic lesions caused by medicinal agents include chronic active hepatitis, steatosis, cirrhosis, fibrosis, hepatoportal sclerosis (non-cirrhotic portal hypertension), hepatic vein thrombosis, peliosis hepatis, adenoma, carcinoma, and angiosarcoma. There is a useful relationship between the type of hepatic injury and the chemical setting in which the drugs are employed. Some agents produce the liver damage because they are intrinsic (true, predictable) hepatotoxins. Other (non-predictable "hepatotoxins"), produce hepatic injury only in the rare and unusually susceptible individual (idiosyncratic injury). Hepatotoxic agents can be recognised by their dose-dependent and experimental reproducibility, properties which are not shared by agents which produce hepatic injury only in idiosyncratic hosts. Intrinsic hepatotoxins may be categorised as direct or indirect. Direct hepatotoxins injure the hepatocyte by direct physiochemical alteration and as a consequence produce metabolic defects. Indirect hepatotoxins selectively block metabolic pathways and, by producing a precise biochemical lesion, lead to structural changes. They may lead to hepatic steatosis or necrosis (cytotoxic indirect hepatotoxins) or block bile flow (cholestatic indirect hepatotoxins). Direct hepatotoxins are rarely encountered as drugs. Overdoses of some drugs and antineoplastic agents appear to be indirect cytotoxic hepatotoxins, and the C-17 alkylated anabolic and contraceptive steroids are indirect, cholestatic hepatotoxins. Idiosyncracy of the host is the mechanism for most types of drug-induced hepatic injury. It may reflect allergy to the drug or a metabolic aberration of the host permitting the production of hepatotoxic metabolites.
用于治疗或诊断目的的大量化学制剂可通过多种机制导致各种类型的肝损伤。急性损伤可能是细胞毒性、胆汁淤积性或混合性的。细胞毒性损伤可能包括坏死或脂肪变性。胆汁淤积性损伤可能是胆小管炎(肝小管性)或单纯性(小管性)的。药物引起的慢性肝损伤包括慢性活动性肝炎、脂肪变性、肝硬化、纤维化、肝门脉硬化(非肝硬化性门脉高压)、肝静脉血栓形成、肝紫癜、腺瘤、癌和血管肉瘤。肝损伤类型与使用药物的化学环境之间存在有益的关系。一些制剂导致肝损伤是因为它们是内在性(真正的、可预测的)肝毒素。其他(不可预测的“肝毒素”)仅在极少数异常易感个体中产生肝损伤(特异质性损伤)。肝毒性制剂可通过其剂量依赖性和实验可重复性来识别,而仅在特异质性宿主中产生肝损伤的制剂则不具备这些特性。内在性肝毒素可分为直接或间接两类。直接肝毒素通过直接的物理化学改变损伤肝细胞,从而产生代谢缺陷。间接肝毒素选择性地阻断代谢途径,并通过产生精确的生化损伤导致结构变化。它们可能导致肝脂肪变性或坏死(细胞毒性间接肝毒素)或阻断胆汁流动(胆汁淤积性间接肝毒素)。直接肝毒素作为药物很少见。某些药物和抗肿瘤制剂的过量使用似乎是间接细胞毒性肝毒素,而C-17烷基化的合成代谢和避孕类固醇是间接胆汁淤积性肝毒素。宿主的特异质性是大多数类型药物性肝损伤的机制。它可能反映对药物的过敏或宿主的代谢异常,从而允许产生肝毒性代谢产物。